Abstract Background and Aim: Despite progress made over the last 30 years, stroke is still a
leading cause of disability and mortality; likewise, its burden is expected to increase over the …

Antiplatelet medications remain a cornerstone of therapy for atherosclerotic cardiovascular
and cerebrovascular diseases. In primary prevention (patients with cardiovascular risk …

Aspirin resistance describes a phenomenon where patients receiving aspirin therapy do not
respond favorably to treatment, and is categorized by continued incidence of adverse …

Ischemic stroke remains the fifth cause of death, as reported worldwide annually.
Endothelial dysfunction (ED) manifesting with lower nitric oxide (NO) bioavailability leads to …

Background: Current guidelines recommend dual antiplatelet therapy for the first 1 to 6
months after transcatheter aortic valve replacement (TAVR); however, recent studies have …

Introduction Amongst the 25.7 million survivors and 6.5 million deaths from stroke between
1990 and 2013, ischemic strokes accounted for approximately 70% and 50% of the cases …

Objective: Patients experiencing acute ischemic stroke or transient ischemic attack are
commonly treated with clopidogrel and/or aspirin (mono-and dual-antiplatelet therapy) to …

Medicinal plants and their extracts have been used as important sources for drug discovery.
In particular, plant-derived natural compounds, including phytochemicals, antioxidants …

Objective The study aimed to compare outcomes of traumatic brain injury (TBI) in patients on
pre-injury antiplatelet drugs vs. those, not on any antiplatelet or anticoagulant drugs …

Purpose: Recent survey studies have demonstrated wide variability in practice patterns
regarding the management of antithrombotic medications in oculofacial plastic surgery …